Last updated: June 6, 2026
Suppliers for Dextrose 5% and Sodium Chloride 0.2% in Plastic Container: Who Makes It, Where Is It Sold, and How to Source
Executive summary: Dextrose 5% and sodium chloride 0.2% (D5W with 0.2% NaCl) in plastic containers is supplied in the US primarily through large hospital-IV portfolio manufacturers and sterile small-volume/nursing-unit distribution networks. The product is typically marketed as an intravenous solution in single-dose plastic bags (commonly PVC or non-PVC multi-layer polymer systems), with supply volume concentrated among a limited set of branded and AB-rated generic manufacturers depending on the packaging configuration (bag size, outlet type, and NDC).
How to use this: Focus sourcing on manufacturers that (1) have consistent sterile liquid manufacturing capacity, (2) list the drug in FDA’s NDC system with the relevant plastic container presentation, and (3) provide reliable distribution for wholesale and GPO channels.
What suppliers offer Dextrose 5% and Sodium Chloride 0.2% IV solution in plastic containers?
Direct answer: In the US market, suppliers are generally limited to companies that manufacture sterile IV solutions at scale and distribute through wholesalers and hospital GPOs. For Dextrose 5% and sodium chloride 0.2% in plastic containers, suppliers typically include:
Common supplier archetype (high-confidence market structure)
- Large sterile IV manufacturers with multi-line bag packaging capability (single-dose plastic).
- Portfolio generics manufacturers that cover common IV diluent solutions (dextrose-saline combinations).
- Hospital supply brand owners that may own the branded product line but source from OEM/contract sterile manufacturing depending on packaging and NDC.
Packaging-specific sourcing reality
“Plastic container” matters because IV solutions can be in different container chemistries:
- PVC bags
- Non-PVC polymer bags (multi-layer systems)
- Different bag sizes (commonly 250 mL, 500 mL, 1000 mL) and outlet configurations
Supply lists should be validated against the exact NDC and bag specification used in your formulary.
Which manufacturers make Dextrose 5% and Sodium Chloride 0.2% in IV bags (PVC vs non-PVC)?
Direct answer: Manufacturing is usually tied to bag type and outlet system. Non-PVC multi-layer packaging is handled by manufacturers with validated container-partner systems and elastomer outlet compatibility. PVC bag configurations are more broadly offered by legacy sterile IV suppliers.
Bag type checks that control supplier eligibility
- Container polymer class (PVC vs non-PVC)
- Elastomeric components and drug-contact materials
- Compatibility with dextrose and saline concentrations
- Sterility assurance and particulate controls for the specific container line
Procurement implication: treat PVC and non-PVC as separate sourcing items even when the label concentration is the same.
What is the FDA-regulated status of Dextrose 5% and Sodium Chloride 0.2% (AB-rated generics vs branded)?
Direct answer: Many IV dextrose-saline combination strengths are marketed either as branded products or as generic equivalents. The presence of multiple suppliers in the US usually indicates generic availability under FDA-reviewed applications, including ANDAs for different container presentations.
Orange Book status: what you should expect
- Multiple NDC entries for the same strength across bag sizes and container systems
- AB or non-AB rating depending on label/route/application matching
- Potential for different holders per NDC even when product is pharmaceutically equivalent
Procurement implication: use NDC-level verification, not just the strength name.
How many suppliers exist for Dextrose 5% and Sodium Chloride 0.2% IV in plastic containers?
Direct answer: The supply market typically supports multiple manufacturers for the same concentration, but the actual count depends on the bag size and container polymer. For hospital purchasing, it is common to see several supplier options for at least the highest-volume bag sizes.
What reduces the supplier count
- Niche bag size formats
- Specific outlet systems
- Non-PVC polymer constraints
- Shortages that force temporary SKU consolidation at the NDC level
What generic entry risks exist for Dextrose 5% and Sodium Chloride 0.2%?
Direct answer: For IV solutions, generic entry risk is mostly commercial and manufacturing-line driven, not academic. The main constraints are:
- sterile liquid batch capacity
- bag/container supply chain
- regulatory maintenance for container-drug compatibility
Operational risk factors that affect supplier continuity
- Container component supply disruption (outlets, overwraps)
- Line downtime or sterility failure events
- Demand surges tied to hospital admission cycles
What formulations are protected for Dextrose 5% and Sodium Chloride 0.2%?
Direct answer: For commonly used IV diluent combinations at these concentrations, IP coverage (when present) usually concentrates on specific container configurations, manufacturing process improvements, or method-of-use claims, rather than the core formulation being exclusively protected.
Formulation patent risk (how it typically shows up)
- Limited exclusivity at the composition level
- More likely differentiation in
- container system and compatibility
- stability-claim methods
- manufacturing process steps
Procurement implication: supplier diversification usually remains feasible once regulatory approvals are in place.
Which companies are challenging supply with outages or limited distribution?
Direct answer: Supply constraints for hospital IV solutions typically appear as temporary SKU unavailability rather than complete product removal. Outage risk is higher during:
- container polymer transition periods
- high utilization seasonal peaks
- manufacturing downtime on specific lines
Actionable sourcing approach: maintain at least two validated NDC alternatives across different container types if your formulary allows.
How to source Dextrose 5% and Sodium Chloride 0.2% in plastic container: checklist for RFP and contracting
Direct answer: The procurement-critical artifacts are the NDC, bag size, and container material.
Buyer checklist
- Exact NDC for the desired bag size and container
- Container type (PVC vs non-PVC) and outlet configuration
- Labeling: “Dextrose 5% and Sodium Chloride 0.2% Injection” with route and storage
- Case pack and distribution terms
- Lead-time and allocation policy in shortages
- Sterility assurance documentation provided via standard lot release channels
Key Takeaways
- Dextrose 5% and sodium chloride 0.2% IV in plastic containers is supplied by multiple sterile-IV manufacturers, but availability depends heavily on NDC-level and bag/container type.
- Procurement should treat bag size and container polymer as separate SKUs for sourcing reliability.
- Generic competition is usually feasible at the product level; supply risk comes more from manufacturing-line capacity and container supply chain than from formulation IP.
FAQs
1) Are PVC and non-PVC Dextrose 5% with 0.2% NaCl considered interchangeable for purchasing?
Usually yes at the concentration level, but no at the NDC/SKU level. Confirm container material and outlet compatibility for your administration pathway.
2) What documents should a supplier provide for sterile IV solutions in plastic containers?
Lot release and standard sterile manufacturing documentation, with NDC-specific labeling and case pack details.
3) How do I validate that a supplier’s product matches my facility’s exact presentation?
Match on NDC plus bag size and container type, then verify labeling and route.
4) What drives shortages for these IV solutions?
Sterile manufacturing line capacity, container component supply (outlets/bags), and demand surges that tighten allocations.
5) Can different manufacturers supply the same strength without switching risk?
Yes if NDC and container compatibility match your protocol, but switching across different containers should be validated by compatibility standards and formulary rules.
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
- FDA National Drug Code Directory (NDC Directory).
